Evidence map›Paper›PMID 35352707›Full record

ArticleBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia2022

Potential novel markers in IBD and CRC diagnostics. Are MMP-19 and RAGE promising candidates?

Pavel Horak, Petr Suhaj, Radoslav Matej, Monika Cervinkova

Open access · goldAbstract read
PubMed Publisher
In one paragraph

Article in Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Pavel HorakDepartment of Surgery, 1st Faculty of Medicine, Charles University in Prague and University Hospital Bulovka, Prague, Czech Republic.
Petr SuhajDepartment of Pathology and Molecular Medicine, 3.
Radoslav MatejDepartment of Pathology and Molecular Medicine, 3.
Monika CervinkovaDepartment of Surgery, 1st Faculty of Medicine, Charles University in Prague and University Hospital Bulovka, Prague, Czech Republic.
Charles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsInflammatory bowel diseases and colorectal cancer are serious intestinal disorders with continuously increasing incidence. Many aspects of etiopathogenesis still remain unclear. There is an urgent need to improve early diagnostics and markers indicating the progression of the disease. The aim of our study was to analyze the expression of matrix metalloproteinase-19 (MMP-19), and the receptor for advanced glycation end-products (RAGE) in different cell subpopulations in inflammatory bowel diseases (IBD) and colorectal cancer (CRC) compared to the tissue in the vicinity of pathological processes.

methodsExpression of both markers in epithelium, macrophages and vessels were evaluated in IBD and CRC groups. They were detected using immunohistochemistry in paraffin sections.

resultsThere were significant differences between the expression of MMP-19 on macrophages and vessels among healthy and cancer tissues. In both, macrophages and vessels were significantly lower levels in cancer tissues. The expression of MMP-19 on vessels was also significantly different between peritumoral and cancer tissues (higher levels in peritumoral tissue). RAGE expression in macrophages was significantly different between healthy and cancer tissues and between peritumoral and cancer tissues. There was significantly lower expression in cancer tissues than in healthy and peritumoral tissues. Expression of RAGE in vessels was significantly different just in the comparison of healthy and peritumoral tissues (higher levels in healthy tissues).

conclusionBoth markers seem to be promising potential auxiliary markers in IBD and CRC diagnostics. They can also improve evaluation of disease progression.

Indexed as

Colorectal NeoplasmsInflammatory Bowel DiseasesBiomarkersHumansMatrix Metalloproteinases, SecretedReceptor for Advanced Glycation End ProductsAGER protein, humanBiomarkersmatrix metalloproteinase 19Matrix Metalloproteinases, SecretedReceptor for Advanced Glycation End Productscolorectal cancerinflammatory bowel diseasematrix metalloproteinasereceptor of advanced glycation end-products

Identifiers

PMID35352707
OpenAlexW4220719393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.